Advances in NKG2D ligand recognition and responses by NK cells

Immunology and Cell Biology

Volumn 92, Issue 3, 2014, Pages 230-236

  Le Bert, Nina ^a   Gasser, Stephan ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cancer; innate immunity; NK cells; NKG2D

Indexed keywords

HEAT SHOCK TRANSCRIPTION FACTOR 1; LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D; NATURAL KILLER CELL RECEPTOR NKG2D LIGAND; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DNA DAMAGE; GLIOBLASTOMA; HEAT SHOCK RESPONSE; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LIVER CELL CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; TARGET CELL; TUMOR CELL;

ANIMALS; CELL LINE, TUMOR; HUMANS; KILLER CELLS, NATURAL; LIGANDS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; SOLUBILITY;

EID: 84899419021     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.111     Document Type: Review

References (99)

1. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44-49.
2. Carlyle JR, Jamieson AM, Gasser S, Clingan CS, Arase H, Raulet DH. Missing selfrecognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc Natl Acad Sci USA 2004; 101: 3527-3532.
3. Iizuka K, Naidenko OV, Plougastel BF, Fremont DH, Yokoyama WM. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat Immunol 2003; 4: 801-807.
4. Karre K. Natural killer cell recognition of missing self. Nat Immunol 2008; 9: 477-480.
5. Lam RA, Chwee JY, Le Bert N, Sauer M, Pogge von Strandmann E, Gasser S. Regulation of self-ligands for activating natural killer cell receptors. Ann Med 2013; 45: 384-394.
6. Raulet D. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781-790.
7. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31: 413-441.
8. Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991; 173: 1017-1020.
9. Wu J, Song Y, Bakker A, Bauer S, Spies T, Lanier L et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730-732.
10. Garrity D, Call ME, Feng J, Wucherpfennig KW. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci USA 2005; 102: 7641-7646.
11. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2Dmediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol 2006; 7: 524-532.
12. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002; 168: 671-679.
13. Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, Vivier E et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 2002; 3: 1142-1149.
14. Gilfillan S, Ho E, Cella M, Yokoyama W, Colonna M. NKG2D recruits two distinct adapters to trigger natural killer cell activation and costimulation. Nat Immunol 2002; 3: 1150-1155.
15. Rosen DB, Araki M, Hamerman JA, Chen T, Yamamura T, Lanier LL. A structural basis for the association of DAP12 with mouse, but not human, NKG2D. J Immunol 2004; 173: 2470-2478.
16. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med 2005; 202: 1001-1012.
17. Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 2001; 167: 5527-5530.
18. Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004; 21: 357-366.
19. Maasho K, Opoku-Anane J, Marusina AI, Coligan JE, Borrego F. NKG2D is a costimulatory receptor for human naive CD8\+ T cells. J Immunol 2005; 174: 4480-4484.
20. Burgess SJ, Marusina AI, Pathmanathan I, Borrego F, Coligan JE. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8\+ T cells. J Immunol 2006; 176: 1490-1497.
21. Burgess SJ, Maasho K, Masilamani M, Narayanan S, Borrego F, Coligan JE. The NKG2D receptor: immunobiology and clinical implications. Immunol Res 2008; 40: 18-34.
22. Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol 2005; 175: 2167-2173.
23. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004; 64: 7596-7603.
24. Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z et al. TGF-beta1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog 2012; 8: e1002594.
25. Espinoza JL, Takami A, Yoshioka K, Nakata K, Sato T, Kasahara Y et al. Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions. Haematologica 2012; 97: 1295-1303.
26. Park YP, Choi SC, Kiesler P, Gil-Krzewska A, Borrego F, Weck J et al. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the gammac cytokines and TGF-beta1. Blood 2011; 118: 3019-3027.
27. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235: 267-285.
28. Strong RK, McFarland BJ. NKG2D and related immunoreceptors. Adv Protein Chem 2004; 68: 281-312.
29. Cerwenka A, Lanier LL. Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev 2001; 181: 158-169.
30. Fernandez-Messina L, Ashiru O, Aguera-Gonzalez S, Reyburn HT, Vales-Gomez M. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells. J Cell Sci 2011; 124: 321-327.
31. Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med 2012; 209: 2409-2422.
32. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996; 93: 12445-12450.
33. Venkataraman GM, Suciu D, Groh V, Boss JM, Spies T. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 2007; 178: 961-969.
34. Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A et al. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle 2011; 10: 3346-3358.
35. Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 2011; 71: 5998-6009.
36. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-1190.
37. Lam AR, Le Bert N, Ho Samantha S, Shen YJ, Tang LF, Xiong G et al. Linkage of DNA sensor signaling pathways and DNA damage response in regulation of Raet1 family NK receptor ligands. Submitted 2013.
38. Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N et al. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 2008; 9: 1065-1073.
39. Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M et al. Host immune system gene targeting by a viral miRNA. Science 2007; 317: 376-381.
40. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverse herpesvirus micro-RNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 2009; 5: 376-385.
41. Bauman Y, Nachmani D, Vitenshtein A, Tsukerman P, Drayman N, Stern-Ginossar N et al. An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host Microbe 2011; 9: 93-102.
42. Eissmann P, Evans JH, Mehrabi M, Rose EL, Nedvetzki S, Davis DM. Multiple mechanisms downstream of TLR-4 stimulation allow expression of NKG2D ligands to facilitate macrophage/NK cell crosstalk. J Immunol 2010; 184: 6901-6909.
43. Tokuyama M, Lorin C, Delebecque F, Jung H, Raulet DH, Coscoy L. Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation. PLoS Pathog 2011; 7: e1002265.
44. Liu XV, Ho SS, Tan JJ, Kamran N, Gasser S. Ras activation induces expression of Raet1 family NK receptor ligands. J Immunol 2012; 189: 1826-1834.
45. Nice TJ, Deng W, Coscoy L, Raulet DH. Stress-regulated targeting of the NKG2D ligand Mult1 by a membrane-associated RING-CH family E3 ligase. J Immunol 2010; 185: 5369-5376.
46. Nice TJ, Coscoy L, Raulet DH. Post translational regulation of the NKG2D ligand Mult1 in response to cell stress. J Exp Med 2009; 206: 287-298.
47. Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008; 68: 6368-6376.
48. Boutet P, Aguera-Gonzalez S, Atkinson S, Pennington CJ, Edwards DR, Murphy G et al. Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 2009; 182: 49-53.
49. Liu G, Atteridge CL, Wang X, Lundgren AD, Wu JD. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chainrelated molecule A independent of A disintegrin and metalloproteinases. J Immunol 2010; 184: 3346-3350.
50. Salih HR, Goehlsdorf D, Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 2006; 67: 188-195.
51. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169: 4098-4102.
52. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66: 2520-2526.
53. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 157-166.
54. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH et al. Disulphide-isomeraseenabled shedding of tumour-associated NKG2D ligands. Nature 2007; 447: 482-486.
55. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 2008; 105: 1285-1290.
56. Fernandez-Messina L, Ashiru O, Boutet P, Aguera-Gonzalez S, Skepper JN, Reyburn HT et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem 2010; 285: 8543-8551.
57. Ashiru O, Boutet P, Fernandez-Messina L, Aguera-Gonzalez S, Skepper JN, Vales-Gomez M et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010; 70: 481-489.
58. Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006; 129: 2416-2425.
59. Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol 2006; 176: 905-913.
60. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumorassociated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-6884.
61. Vetter CS, Lieb W, Brocker EB, Becker JC. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br J Cancer 2004; 91: 1495-1499.
62. Vetter CS, Groh V, thor Straten P, Spies T, Brocker EB, Becker JC. Expression of stressinduced MHC class I related chain molecules on human melanoma. J Invest Dermatol 2002; 118: 600-605.
63. Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF et al. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun 2007; 7: 17.
64. Textor S, Durst M, Jansen L, Accardi R, Tommasino M, Trunk MJ et al. Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 2008; 123: 2343-2353.
65. Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W et al. Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. Neoplasia 2009; 11: 662-671.
66. Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO et al. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer 2006; 118: 1445-1452.
67. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007; 109: 4816-4824.
68. Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 2013; 210: 2057-2069.
69. Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H et al. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 2009; 58: 641-652.
70. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005; 105: 2066-2073.
71. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005; 6: 928-937.
72. Wiemann K, Mittrucker HW, Feger U, Welte SA, Yokoyama WM, Spies T et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005; 175: 720-729.
73. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer 2006; 118: 684-687.
74. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 2006; 55: 1584-1589.
75. Ye YB, Zhou ZF, Chen Q, Li JY, Chen X, Huang WW. [The roles of soluble MICA in immune escape of breast tumor]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2008; 24: 904-907.
76. Rebmann V, Schutt P, Brandhorst D, Opalka B, Moritz T, Nowrousian MR et al. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol 2007; 123: 114-120.
77. Nuckel H, Switala M, Sellmann L, Horn P, Durig J, Duhrsen U et al. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 2010; 24: 1152-1159.
78. Tamaki S, Sanefuzi N, Kawakami M, Aoki K, Imai Y, Yamanaka Y et al. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. Hum Immunol 2008; 69: 88-93.
79. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389-1396.
80. Zhao S, Wang H, Nie Y, Mi Q, Chen X, Hou Y. Midkine upregulates MICA/B expression in human gastric cancer cells and decreases natural killer cell cytotoxicity. Cancer Immunol Immunother 2012; 61: 1745-1753.
81. Marten A, von Lilienfeld-Toal M, Buchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 2006; 119: 2359-2365.
82. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004; 114: 560-568.
83. Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012; 189: 1360-1371.
84. Nuckel H, Switala M, Sellmann L, Horn PA, Durig J, Duhrsen U et al. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 2010; 24: 1152-1159.
85. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738.
86. Diefenbach A, Jensen ER, Jamieson AM, Raulet D. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-171.
87. Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K et al. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol 2011; 28: 466-474.
88. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005; 43: 1013-1020.
89. Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 2008; 8: 16.
90. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009; 9: 568-580.
91. Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen X et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009; 15: 5208-5215.
92. Sancar A, Lindsey-Boltz LA, Unsal-Kaccmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73: 39-85.
93. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-870.
94. Halazonetis T, Gorgoulis V, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319: 1352-1355.
95. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007; 130: 1005-1018.
96. Lee YJ, Lee HJ, Lee JS, Jeoung D, Kang CM, Bae S et al. A novel function for HSF1-induced mitotic exit failure and genomic instability through direct interaction between HSF1 and Cdc20. Oncogene 2008; 27: 2999-3009.
97. Tang D, Khaleque MA, Jones EL, Theriault JR, Li C, Wong WH et al. Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones 2005; 10: 46-58.
98. Fionda C, Soriani A, Malgarini G, Iannitto ML, Santoni A, Cippitelli M. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J Immunol 2009; 183: 4385-4394.
99. Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 2006; 176: 5108-5116.